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Abstract
Background: Drug-drug interactions resulting from the inhibition of an enzymatic process can have serious implications for
clinical drug therapy. Quantification of the drugs internal exposure increase upon administration with an inhibitor requires
understanding to avoid the drug reaching toxic thresholds. In this study, we aim to predict the effect of the CYP3A4 inhibitors,
itraconazole (ITZ) and its primary metabolite, hydroxyitraconazole (OH-ITZ) on the pharmacokinetics of the anesthetic,
midazolam (MDZ) and its metabolites, 1' hydroxymidazolam (1OH-MDZ) and 1' hydroxymidazolam glucuronide (1OH-MDZ-
Glu) using mechanistic whole body physiologically-based pharmacokinetic simulation models. The model is build on MDZ, 1OH-
MDZ and 1OH-MDZ-Glu plasma concentration time data experimentally determined in 19 CYP3A5 genotyped adult male
individuals, who received MDZ intravenously in a basal state. The model is then used to predict MDZ, 1OH-MDZ and 1OH-
MDZ-Glu concentrations in an CYP3A-inhibited state following ITZ administration.
Results: For the basal state model, three linked WB-PBPK models (MDZ, 1OH-MDZ, 1OH-MDZ-Glu) for each individual were
elimination optimized that resulted in MDZ and metabolite plasma concentration time curves that matched individual observed
clinical data. In vivo Km and Vmax optimized values for MDZ hydroxylation were similar to literature based in vitro measures.
With the addition of the ITZ/OH-ITZ model to each individual coupled MDZ + metabolite model, the plasma concentration
time curves were predicted to greatly increase the exposure of MDZ as well as to both increase exposure and significantly alter
the plasma concentration time curves of the MDZ metabolites in comparison to the basal state curves. As compared to the
observed clinical data, the inhibited state curves were generally well described although the simulated concentrations tended to
exceed the experimental data between approximately 6 to 12 hours following MDZ administration. This deviations appeared
to be greater in the CYP3A5 *1/*1 and CYP3A5 *1/*3 group than in the CYP3A5 *3/*3 group and was potentially the result of
assuming that ITZ/OH-ITZ inhibits both CYP3A4 and CYP3A5, whereas in vitro inhibition is due to CYP3A4.
Conclusion: This study represents the first attempt to dynamically simulate metabolic enzymatic drug-drug interactions via
coupled WB-PBPK models. The workflow described herein, basal state optimization followed by inhibition prediction, is novel
and will provide a basis for the development of other inhibitor models that can be used to guide, interpret, and potentially
replace clinical drug-drug interaction trials.
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Background
Drug-drug interactions resulting from the inhibition of an
enzymatic process can have serious implications for clini-
cal therapy. Quantifying the magnitude of the inhibitor
effect in vivo is an active area of study although methods
of quantifying the exposure increase of a drug concomi-
tantly administered with an inhibitor have focused on,
until now, simplistic, static models [1-3]. These
approaches assume that there is a proportional increase in
exposure at high inhibitor concentrations and do not
account for the time course of inhibitor concentrations.
The approach that is taken is one which dynamically links
inhibitor and drug models using whole-body physiologi-
cally-based pharmacokinetic models (WB-PBPK) to quan-
tify, under any administration time and dose regimen, the
changes that occur in parent compound exposure as well
as the dynamic changes in the respective metabolite expo-
sures. This has been done for midazolam (MDZ), and its
two major metabolites 1' hydroxymidazolam (1OH-
MDZ) and the glucuronide of 1' hydroxymidazolam
(1OH-MDZ-Glu), in the presence of the CYP3A4 inhibi-
tors itraconazole (ITZ) and its major metabolite hydroxy-
itraconazole (OH-ITZ). This example was used because of
the importance of CYP3A4 to drug metabolism and the
availability of a full clinical data set for MDZ given in the
basal and ITZ/OH-ITZ inhibited state [4].
Cytochrome P450 (P450) enzymes play an important role
in the metabolism of exogenous and endogenous mole-
cules. In humans, CYP3A represents one of the most
important subfamilies of the P450 superfamily. CYP3A4
is the major P450 in the liver and intestine and has been
reported to be involved in the metabolism of more than
60% of all medically relevant drugs [5]. The expression of
CYP3A5 is highly polymorphic, due to a single nucleotide
polymorphism, which is designated CYP3A5*3 [6]. Pop-
ulation frequencies for CYP3A5 variants in mixed Ameri-
can and Korean individuals are 61–77% for CYP3A5*3/
*3, 22–33% for CYP3A5*1/*3 and 1–5% for CYP3A5*1/
*1 [4,7] with CYP3A5*3/*3, CYP3A5*1/*3 and
CYP3A5*1/*1 constituting 5%, 50% and 76% of the total
CYP3A concentration, respectively. Total CYP3A content
was more than 2-fold higher for livers with at least one
CYP3A5*1 allele compared with CYP3A5*3/*3 livers [7].
Because CYP3A5 exhibits an overlapping substrate specif-
icity with that of CYP3A4, it may contribute significantly
to the metabolic elimination of CYP3A substrates in peo-
ple carrying the wild-type CYP3A5*1 allele, although in
vivo data as well as in vitro evidence are conflicting [4,8].
Because CYP3A is significantly involved in drug biotrans-
formation, drug-drug interactions resulting from the inhi-
bition of CYP3A-mediated metabolism by a co-
administered therapeutic agent are of clinical importance.
MDZ is a short-acting benzodiazepine that is primarily
metabolized in the liver and gut wall by CYP3A4 and
CYP3A5 [9,10]. The major active metabolite 1-hydrox-
ymidazolam (1-OH-MDZ) and the minor metabolite 4-
hydroxymidazolam (4-OH-MDZ) can be further hydroxy-
lated to yield 1,4-dihydroxymidazolam (1,4-di-OH-
MDZ) [9]. All metabolites are rapidly converted to their
glucuronide conjugates by uridine diphosphate-glucuron-
osyl-transferases (UGTs) (Figure 1a) and excreted into the
urine [10,11]. Within 24 h, 60% to 80% of a MDZ dose is
excreted in the urine as 1-OH-MDZ-Glu, 3% as 4-OH-
MDZ-Glu and 1% as 1,4-di-OH-MDZ-Glu [11,12]. No
significant amounts of parent drug or primary metabolites
are extractable from urine [12].
Itraconazole (ITZ) is an orally active triazole antimycotic
agent, which is active against a broad spectrum of fungal
species. ITZ is extensively metabolized in humans, yield-
ing over 30 metabolites, including its primary active
metabolite hydroxy-itraconazole (OH-ITZ). ITZ and its
subsequent sequential metabolites [OH-ITZ, keto-itraco-
nazole (keto-ITZ) and N-desalkyl-itraconazole (ND-ITZ)]
are all high affinity ligands and substrates of CYP3A4 [13].
ITZ and OH-ITZ are also competitive inhibitors of
CYP3A4. Keto-ITZ and ND-ITZ may also contribute to
CYP3A4 inhibition in vivo following ITZ therapy, but
their concentration following ITZ administration is signif-
icantly lower resulting in a low inhibitory influence [13].
In this study, we aim to predict the effect of ITZ and OH-
ITZ CYP3A4 inhibition following oral ITZ administration
on the pharmacokinetics of intravenously administered
MDZ using a mechanistic WB-PBPK simulation model.
WB-PBPK modeling allows for the simulation of the fate
of xenobiotics in the human body on the basis of individ-
ual physiological characteristics [14]. The model is build
on MDZ, 1OH-MDZ and 1OH-MDZ-Glu plasma concen-
tration time data experimentally determined in 19
CYP3A5 genotyped adult male individuals, who received
MDZ intravenously in basal and ITZ-inhibited CYP3A
metabolic states [4]. At first, three WB-PBPK models, one
for MDZ, one for 1OH-MDZ and one for 1OH-MDZ-Glu,
will be coupled per individual to dynamically simulate
the kinetics of MDZ hydroxylation and glucuronidation
for each study volunteer. In a second step, the MDZ mod-
els will be extended by linking WB-PBPK models of ITZ
and OH-ITZ in order to predict the interaction between
MDZ and ITZ via ITZ and OH-ITZ-mediated CYP3A4-
inhibition in a time-dependent manner.
Results
The simulated plasma concentration time curves follow-
ing intravenous administration of MDZ and 1OH-MDZ
adequately represented the corresponding in vivo time
course data reported by Mandema et al. [15] (Figure 2).Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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Figure 3 presents the mean (± standard deviation) of the
six individual optimized plasma concentration time pro-
files for MDZ and 1OH-MDZ (lines) along with the mean
(± standard deviation) of the experimental data (symbols)
[11]. The elimination optimized curves matched the
experimental data well. Table 1 presents the minimum,
mean and maximum velocity-rate constants (k1,-1,2), Km,
Vmax,Vmax/Km and CL(1OH) values which were the results
of the individual optimizations for the six individuals.
The optimized plasma concentration time profiles for
MDZ, 1OH-MDZ and 1OH-MDZ-Glu (lines) are pre-
sented in Figure 4 together with the experimental data
(symbols) [16]. The elimination optimized curves well
represented the experimental data. Numerical results are
shown in Table 1.
Figure 5 presents the mean (± standard deviation) opti-
mized plasma concentration time profiles for MDZ and
the sum of 1OH-MDZ and 1OH-MDZ-Glu (lines) along
with the mean experimental data (symbols) separated by
the CYP3A5 genotype group [4]. The elimination opti-
mized curves well represented the experimental data. The
mean [range] of the resulting 1OH_Km and 1OH_Vmax val-
ues for the hydroxylation were 2.1 umol/L [0.69–5.0] and
3.4E-4 umol/min [1.0E-4 – 7.2E-4], respectively. For the
glucuronidation, the mean [range] of the resulting
Glu_Km and Glu_Vmax values were 0.21 umol/L [1.2E-4 –
1.5] and 4.0E-3 umol/min [2.0E-5–4.7E-2], respectively.
The mean [range] of the optimized renal elimination of
1OH-MDZ-Glu was 13.2 L/min [5.1–34.9].
In Figure 6, the individuals from the Yu et al [4] are ranked
according to their Km and Vmax values for the hydroxyla-
tion, normalized to the mean. There is no correlation
between the CYP3A5 genotype and the affinity of MDZ to
CYP3A (Km) or the rate of hydroxylation (Vmax) in the
basal state.
Figure 7 presents the simulated ITZ plasma concentration
time curve following 200 mg dosing of ITZ in the fed state
as compared to experimental data from Barone et al. [17]
for the first day and Hardin et al. [18] for the trough con-
centrations on subsequent days. The fraction of remaining
CYP3A activity resulting from the simulated unbound
intracellular concentrations of ITZ and OH-ITZ in the liver
over time is also presented in Figure 7.
Figure 5 also presents the mean (± standard deviation)
predicted plasma concentration time profiles for MDZ
and the sum of 1OH-MDZ and 1OH-MDZ-Glu (lines)
along with the mean experimental data (symbols) sepa-
a) Schematic representation of the CYP3A4-, CYP3A5- and UGT-catalyzed metabolic pathway for MDZ Figure 1
a) Schematic representation of the CYP3A4-, CYP3A5- and UGT-catalyzed metabolic pathway for MDZ. The percentages of 
the administered MDZ dose which are excreted in the urine within 24 hours [11,12] are given below the compounds. Abbre-
viations: MDZ, midazolam; 1OH-MDZ, 1-hydroxymidazolam; 4OH-MDZ, 4-hydroxymidazolam; 1,4-di-OH-MDZ, 1,4-dihy-
droxymidazolam; 1OH-MDZ-Glu, 1-hydroxymidazolam glucuronide; 1,4-di-OH-MDZ-Glu, 1,4-dihydroxymidazolam 
glucuronide; 4-OH-MDZ-Glu, 4-hydroxymidazolam glucuronide; UGT, uridine diphosphate-glucuronosyl-transferase. b) Sche-
matic representation of the simplified metabolic pathway for MDZ used in the coupled model approach.Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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rated by the CYP3A5 genotype group following ITZ
administration [4]. MDZ exposure increases with a conse-
quent decrease in initial 1OH-MDZ+1OH-MDZ-Glu con-
centrations and increase at later time points. While the
shape of the curve is generally well described, the simu-
lated concentrations tend to exceed the experimental data
between approximately 6 to 12 hours. This deviations
appears to be greater in the CYP3A5 *1/*1 and
CYP3A5*1/*3 group than in the CYP3A5 *3/*3 group.
Discussion
A dynamic, coupled WB-PBPK model of MDZ and its
metabolites was developed to predict the time-dependent
interaction of MDZ when co-administered with the
CYP3A4 inhibitor ITZ. This novel method differs greatly
from previously used models to identify the potential for
drug-drug interactions. Static models generally prevail
where competitive and irreversible inhibition is defined
by the kinetic parameters of the inhibitor and are only
dose dependent in relation to the inhibitor [2,3]. Using
the static model, a ratio of basal state area under the curve
(AUC) to inhibited state AUC is calculated, which pro-
vides a means of estimating the mean extent of inhibition
in a given time period. Identifying parent compound and
metabolite curve shape changes along with the generation
of any metabolite profiles is not possible using this
method. Since the static nature of these models limits
their flexibility, dynamically interacting WB-PBPK models
were seen as the method of choice for understanding how
drug-drug interactions affect pharmacokinetic profiles of
both the parent compound and its metabolites. Recently,
Özdemir et al. [19] presented an attempt to predict the
drug-drug interaction of MDZ with another antifungal
agent, ketoconazole by means of the AUC increase of
MDZ when co-administered with KTZ, and concluded
that comprehensive PBPK models are required to correctly
predict the inhibitory effect of ketoconazole.
The study of Yu et al. [4] provided an excellent data set of
anthropometric (weight, height, age) data, CYP3A5 geno-
type and plasma concentration profiles for 19 individuals
given MDZ alone and in combination with ITZ. Using this
experimental data, each basal state individual MDZ and
metabolite profile was optimized and, followed by the
addition of the ITZ data and models, was used to test the
Mean of the predicted plasma concentration time curves  (line) of MDZ and 1OH-MDZ following an intravenous  administration of 0.15 mg/kg as compared to the mean (n =  6) of the experimental data Figure 3
Mean of the predicted plasma concentration time curves 
(line) of MDZ and 1OH-MDZ following an intravenous 
administration of 0.15 mg/kg as compared to the mean (n = 
6) of the experimental data. Experimental data was taken 
from Heizmann et al. [11].
Simulated plasma concentration time curve (line) of a) MDZ  following a 15 minute intravenous infusion of 0.1 mg/kg MDZ  and b) 1OH-MDZ following a 15 minute intravenous infusion  of 0.15 mg/kg 1OH-MDZ as compared to mean experimental  data Figure 2
Simulated plasma concentration time curve (line) of a) MDZ 
following a 15 minute intravenous infusion of 0.1 mg/kg MDZ 
and b) 1OH-MDZ following a 15 minute intravenous infusion 
of 0.15 mg/kg 1OH-MDZ as compared to mean experimental 
data. Experimental data was taken from Mandema et al. [15].Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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model's ability to predict the MDZ-ITZ drug-drug interac-
tion potential.
In a first step, the MDZ plus metabolite model was devel-
oped. Distribution properties of MDZ, 1OH-MDZ and
1OH-MDZ-Glu in this study were based on previously
established mechanistic models to estimate organ parti-
tioning parameters [14,20,21]. Four out of 17 organ par-
tition coefficients were ultimately modified using
experimental partition coefficients for MDZ scaled from
rats [22]. For MDZ and 1OH-MDZ, this modification
accurately led to simulated plasma concentration time
profiles that mirrored observed profiles following IV
administration.
The subsequent coupling of MDZ, 1OH-MDZ and 1OH-
MDZ-Glu was achieved using velocity rate constants for
metabolism parameterization. Using a step wise process
inclusive of different experimental data sets [11,16], the
velocity rate constants that defined the basal state kinetics
of MDZ, 1OH-MDZ and 1OH-MDZ-Glu, were optimized
for our study data [4]. In order to evaluate the optimiza-
tion results, 1OH_Km values were compared to in vitro
findings. The mean ± SD 1OH_Km values for the Heiz-
mann et al. [11], Kharasch et al. [16] and Yu et al. [4] data
sets were 2.2 ± 0.99 umol/L, 5.3 umol/L and 2.1 ± 1.17
umol/L, respectively. These were all similar to each other
and also to the in vitro mean ± SD 1OH_Km = 3.9 ± 3.1
umol/L reported by Patki et al. [23]. The coefficient of var-
iability (CV%) for 1OH_Km  and 1OH_Vmax were also
compared to in vitro findings to evaluate the reasonability
of the generated inter-individual variation. The in vitro
CV% for 1OH_Km and 1OH_Vmax generated from human
liver microsomes (HLMs) of twelve individuals being
80% and 58%, respectively [23], were similar to the
results of the optimization of the Yu et al. [4] data, namely
1OH_Km CV% = 57% and 1OH_Vmax CV% = 47%. There-
fore, there is a correlation between in vitro and in vivo
1OH_Km and 1OH_Vmax for the hydroxylation of MDZ via
CYP3A4/5. Furthermore, the individual 1OH_Vmax varia-
bility was linked to the underlying process by comparing
the CV% of 1OH_Vmax  with that of in vitro hepatic
CYP3A4/5 concentration. The CV% for the CYP3A4/5
concentration in a group of Japanese, Caucasian and
mixed Americans was 160% [23,24] whereas that for the
Japanese population alone was 35% [24]. The CV% of
Vmax for the Koreans of the Yu et al. [4] data, 47%, is
between both values and closer to that for the Japanese
population. This suggests that our model was able to cap-
ture the inter-individual variability in hepatic CYP3A con-
centration using 1OH_Vmax as a surrogate.
The enzyme responsible for the glucuronidation of 1OH-
MDZ is unknown. In order to estimate the relevant UDP-
glucuronosyltransferase (UGT) concentration, the find-
ings by Reinach et al. [25] were used. They observed that
the metabolism of MDZ was 0.080 nmol/min/106 cells
Predicted plasma concentration time curves (lines) of MDZ,  1OH-MDZ and 1OH-MDZ-Glu following an intravenous  bolus administration of 1 mg MDZ as compared to experi- mental data from a typical individual (symbols) Figure 4
Predicted plasma concentration time curves (lines) of MDZ, 
1OH-MDZ and 1OH-MDZ-Glu following an intravenous 
bolus administration of 1 mg MDZ as compared to experi-
mental data from a typical individual (symbols). Experimental 
data was taken from Kharasch et al. [16].
Table 1: Mean, minimum and maximum parameter values from 
the optimization of the coupled WB-PBPK model using the 
Heizmann et al. [11] data (n = 6) and the Kharasch et al. [16] 
mean data.
Heizmann Kharasch
Parameter Mean Min Max Mean
1OH_k1 [L·umol-1·min-1] 5.6E-2 4.1E-2 7.4E-2 2.7E-2
1OH_k-1 [min-1] 8.1E-6 4.3E-21 4.8E-5 1.1E-11
1OH_k2 [min-1] 0.12 0.086 0.24 0.14
CL(1OH) [L·min-1]7 5 . 1 5 6 . 7 9 7 . 4
1OH_Km [umol·L-1] 2.2 1.4 3.9 5.3
1OH_Vmax [umol·min-1·gtissue
-1] 3.4E-4 2.2E-4 6.6E-4 4.0E-4
Glu_k1 [L·umol-1·min-1]1 . 1
Glu_k-1 [min-1] 2.6E-9
Glu_k2 [min-1] 0.11
Glu_Km [umol·L-1] 0.10
Glu_Vmax [umol·min-1·gtissue
-1] 7.7E-5
CL(Glu) [L·min-1] 14.5Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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Mean ± standard deviation plots of the experimental observed plasma concentration time profiles for MDZ and the sum of its  metabolites, 1OH-MDZ and 1OH-MDZ-Glu (symbols: squares) and the corresponding mean elimination optimized curves  (solid lines) for the CYP3A5 genotypes, CYP3A5 *1/*1 (n = 6), CYP3A5 *1/*3 (n = 6) and CYP3A5*3/*3 (n = 7) in the basal  state Figure 5
Mean ± standard deviation plots of the experimental observed plasma concentration time profiles for MDZ and the sum of its 
metabolites, 1OH-MDZ and 1OH-MDZ-Glu (symbols: squares) and the corresponding mean elimination optimized curves 
(solid lines) for the CYP3A5 genotypes, CYP3A5 *1/*1 (n = 6), CYP3A5 *1/*3 (n = 6) and CYP3A5*3/*3 (n = 7) in the basal 
state. Also presented is the mean ± standard deviation plots of the experimental observed plasma concentration time profiles 
for MDZ and the sum of its metabolites, 1OH-MDZ and 1OH-MDZ-Glu (symbols: circles) and the corresponding mean pre-
dicted curves (dotted lines) for the CYP3A5 genotypes in the CYP3A inhibited state resulting from ITZ administration. Plasma 
concentration time curves in the inhibited state were graphed starting at time = 0 to allow for direct comparison with the basal 
state curves. Experimental data was taken from Yu et al. [4].
Midazolam (mean and s.d.) Metabolites (mean and s.d.)Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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while the metabolism of 1OH-MDZ was 0.020 nmol/
min/106 cells in human hepatocytes. As there was no
additional information available, for our study, it was
assumed that the difference between the metabolism of
MDZ and 1OH-MDZ was only dependent on differing
enzyme concentration. Under this assumption, the UGT
concentration was estimated, namely [UGT] = 0.25
[CYP3A]. The absolute Glu_Km and Glu_Vmax values are
therefore provisional. Nevertheless, the optimized curves
will not change when the actual UGT concentration is
known, as the product of the velocity-rate constants and
the enzyme concentration were optimized. Thus, if the
enzyme concentration changes, then k1, k-1 and k2 can
change accordingly (see equation 1) therefore changing
the calculated Km (see equation 2, no steady state assump-
tion is made) and Vmax values (see equation 3). Despite
that the absolute Km and Vmax values are dependent on the
enzyme concentration, inter-individual variability is inde-
pendent of the absolute values. It is remarkable that the
CV% of Glu_Km  was relative high with 191%. For
Glu_Vmax, the CV% equaled 299%. This was substantially
higher than the CV% for 1OH_Vmax. As the CV% for Vmax
can be linked to the underlying process, or more precisely
the enzyme concentration, it can be inferred that the inter-
individual variability of the corresponding UGT concen-
tration might be higher than that of the CYP3A concentra-
tion. This hypothesis cannot be confirmed nor rejected
because the UGT(s) catalyzing the glucuronidation of
1OH-MDZ or similar compounds are unknown. Once the
UGT(s) catalyzing the glucuronidation of 1OH-MDZ and
its (their) concentration is known, Glu_Km and Glu_Vmax
can be recalculated and further interpreted.
The information about the contribution of CYP3A5 to
overall MDZ metabolism is controversial. According to
Huang et al. [8], CYP3A5 accounts for 27% of the total
product formation catalyzed by microsomes with at least
one CYP3A5*1 allele, whereas Williams et al. [26] reports
that CYP3A4 and CYP3A5 contribute equally to the MDZ
elimination. Other in vitro studies demonstrate that
CYP3A5 has a higher catalytic activity but a lower affinity
than CYP3A4 for MDZ 1-hydroxylation [8,23,26]. Despite
the fact that the in vitro studies consistently suggested an
influence of the CYP3A5 concentration on the MDZ elim-
ination, in vivo findings have been inconsistent. A higher
MDZ elimination for white cancer patients [27] and
healthy Asian subjects [28] having at least one wild-type
CYP3A5*1 allele compared to CYP3A5*3/*3 patients
have been reported. In contrast, Floyd et al. [29] and Shih
& Huang [30] found no effect of the CYP3A5 genotype on
the elimination of MDZ in a mixed population of healthy
white and African American adults and Chinese volun-
Simulated (line) ITZ plasma concentration time curve follow- ing 15 days of 200 mg once per day ITZ administration in the  fed state Figure 7
Simulated (line) ITZ plasma concentration time curve follow-
ing 15 days of 200 mg once per day ITZ administration in the 
fed state. Mean experimental data (symbols: squares) for the 
first day was taken from Barone et al. [17] and experimental 
data (mean ± SD, symbols: circles) was taken from Hardin et 
al. [18]. The inset graph presents the estimated fraction of 
remaining CYP3A activity over time as a result of ITZ and 
OH-ITZ inhibition.
Rank-order plots for the optimized 1OH_Km and 1OH_Vmax  values normalized to the mean Figure 6
Rank-order plots for the optimized 1OH_Km and 1OH_Vmax 
values normalized to the mean.Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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teers, respectively. Figure 6 represents the rank-order plot
for the optimized 1OH_Km and 1OH_Vmax values for the
Yu et al. [4] data. The result of this figure supports the
hypothesis that CYP3A5 plays little to no role in MDZ
hydroxylation and is the same result presented in the Yu
et al. [4] study in the basal state.
In a second step, a WB-PBPK model for ITZ and OH-ITZ
was developed and linked to in vitro data of their CYP3A4
inhibition potential. Through dynamically linking the
inhibitor models with MDZ, and thus the MDZ-metabo-
lite models, a prediction of the effect of ITZ given at 200
mg per day over 5 days could be made for each individual
from the Yu et al. [4] study. One assumption of our model
was that ITZ inhibits total CYP3A activity whereas it is
actually specific to the inhibition of CYP3A4. The poten-
tial consequences of this were observed when MDZ was
modeled in the presence of ITZ and OH-ITZ. There was a
slight overprediction of the mean predicted plasma con-
centrations in relation to those observed between 6 and
12 hours, which was greater in individuals with at least
one CYP3A5*1 allele. Since these individuals have a
greater proportion of CYP3A5 relative to their total
CYP3A content, this suggests that CYP3A5 remains un-
inhibited by ITZ and OH-ITZ and thus can contribute to
MDZ elimination. By comparing the observed and pre-
dicted MDZ pharmacokinetic profiles in the basal and
inhibited states, the relative contribution of CYP3A5 to
overall MDZ elimination in vivo is low regardless of the
CYP3A5 genotype. Even in light of this model simplifica-
tion, the resulting simulations adequately predicted the
changes in the MDZ profiles as well as predicting the com-
pletely different MDZ metabolite profiles in the inhibited
state.
While dynamic simulations of drug-drug interactions are
desirable, their conceptualization and implementation
are complex compared to the static AUC ratio method, as
described above. Major limitations are the availability of
pharmacokinetic data for the compound of interest and
the inhibitor (especially if multiple metabolites are of
concern) as well as a lack of thoroughly studied in vitro
inhibition data. Simplification of the model is necessary
when this data is not available, which may limit the flexi-
bility and application of the model. In our case, the sim-
plification of the CYP3A complex is one such example.
The data that was required to incorporate both a CYP3A4
and CYP3A5 enzyme into the liver was limited by a lack
of data on how much each enzyme contributed to 1OH-
MDZ plasma concentrations. Further, no individual ITZ
plasma concentration time data was available and thus a
mean curve had to be generated and used for each individ-
ual. Knowing these limitations ahead of gathering the
experimental data, may help to inform the clinical drug-
drug interaction trial by guiding the planning stage.
Conclusion
This study represents the first attempt to dynamically sim-
ulate metabolic enzymatic drug-drug interactions via cou-
pled WB-PBPK models. The workflow described herein,
basal state optimization followed by inhibition predic-
tion, is novel and will provide a basis for the development
of other inhibitor models that can be used to guide, inter-
pret, and potentially replace clinical drug-drug interaction
trials.
Methods
WB-PBPK model development and parameterization for 
defining MDZ CYP3A-mediated metabolism
PK-Sim®  (ver 3.0, Bayer Technology Services GmbH,
Leverkusen, Germany) was used to generate the individ-
ual WB-PBPK models for MDZ, 1OH-MDZ and 1OH-
MDZ-Glu. PK-Sim® is a commercially available software
tool for WB-PBPK modeling of drugs in laboratory ani-
mals and humans. It uses validated physiological models
to estimate substance-specific absorption [21] and distri-
bution parameters, such as organ/plasma partition coeffi-
cients and permeability coefficients, from physico-
chemical properties of a compound such as lipophilicity,
plasma protein binding, molecular weight and solubility
[14,20,21]. Physiological databases are included in the
software that incorporate the dependencies of organ
weights, organ blood flows and intestinal parameters [gas-
trointestinal length, radius of each section, intestinal sur-
face area [21]] with the weight and height of the
individual [31]. For a detailed description of the WB-
PBPK model structure implemented in PK-Sim®, see Will-
mann et al. [14,20,21].
Individual coupled WB-PBPK models, inclusive of MDZ
and its metabolites, were set up. First, the MDZ WB-PBPK
model was parameterized by inputting the physico-chem-
ical properties of MDZ (Table 2), the weight of the indi-
vidual, a mean height and the application regime into PK-
Sim®. The MDZ WB-PBPK model contains a hepatic elim-
ination process, defined in the liver intracellular space,
describing the CYP3A mediated elimination of MDZ to its
metabolite, 1OH-MDZ. This metabolism process was
defined in the model assuming Michaelis-Menten kinetics
(Figure 1b). The Michaelis-Menten mechanism for
enzyme catalysis takes into account that the substrate [S]
and the enzyme [E] first form a complex [ES] before the
substrate is converted into the product [P]:
The micro-constants k1, k-1 and k2 are velocity-rate con-
stants for the association of substrate and enzyme, the dis-
sociation of unaltered substrate from the enzyme and the
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dissociation of product from the enzyme, respectively. At
steady-state the following equation is valid,
k1 [E0][S] = k-1[ES] + k2[ES]   (1)
with [I] being the concentration of the compound I. The
Michaelis-Menten constant Km can be calculated from the
micro-constants as follows:
The maximum velocity of the reaction (Vmax) depends on
the total enzyme concentration [E]total and the rate of the
second reaction step:
Vmax = k2[E]total   (3)
The intrinsic clearance (CL) is the rate constant of metab-
olization and is defined by the Michaelis-Menten equa-
tion:
Under the condition that the substrate concentration [S]
is much smaller than Km, the intrinsic clearance
approaches the ratio of Vmax and Km:
Furthermore, the simplified model includes a CYP3A
complex, which represents both iso-enzymes (CYP3A4
and CYP3A5) in the human liver. It is not possible to
model the reactions catalyzed by CYP3A4 and CYP3A5
separately, as it is not clearly understood how much each
contributes to the production of 1OH-MDZ. Therefore, an
assumption has to be made, namely that the CYP3A com-
plex is sufficient to model MDZ-ITZ interactions.
Following generation of a MDZ WB-PBPK model, the WB-
PBPK models for 1OH-MDZ and 1OH-MDZ-Glu were
parameterized by inputting 1OH-MDZ and 1OH-MDZ-
Glu physico-chemical data (Table 2). All physiological
model parameters such as age, weight, height and all
depending parameters such as organ weights and blood-
flow rates remained the same as in the MDZ model of the
same individual. Since 1OH-MDZ is cleared in the liver
via glucuronidation, the 1OH-MDZ WB-PBPK model con-
tains a hepatic elimination of 1OH-MDZ to its glucuro-
nide, 1OH-MDZ-Glu via UGT, defined by velocity rate
constants (k1,-1,2) as described above in Eq.(1). Elimina-
tion of 1OH-MDZ-Glu [CL(Glu)] from the circulation
was defined by a first order intrinsic elimination process
in the kidney. Coupling of the three WB-PBPK models was
done such that the source function generating 1OH-MDZ
in the liver intracellular volume was equal to the output of
the CYP3A mediated elimination of MDZ (on a molar
basis). In the same way, the source function of 1OH-
MDZ-Glu was equal to the output of the UGT mediated
elimination of 1OH-MDZ within the liver intracellular
space.
Enzyme concentration
Hepatic enzyme concentrations in the individuals from
where the study data was derived were unknown. Thus,
typical enzyme concentrations had to be taken from the
literature. The median CYP3A complex concentration of a
mixed and a Japanese population was used as the enzyme
concentration for the hydroxylation step in this study,
such that [E0] equaled 70 pmol/mgmicrosomal protein
[7,23,24]. The value 40 mg protein/gliver [32-34] was used
to yield [CYP3A] = 2.8 nmol/gliver. The specific enzyme
responsible for the glucuronidation of 1OH-MDZ is not
known. Reinach et al. [25] measured the metabolism of
MDZ using thawed human hepatocytes and found that
the metabolism of MDZ to 1OH-MDZ is four times higher
than the metabolism of 1OH-MDZ to 1OH-MDZ-Glu.
This ratio was used to estimate a UGT concentration,
namely [UGT] = 0.25× [CYP3A]. These enzyme concentra-
tion values remained the same for all individuals. There-
fore, all of the variability in calculated Vmax values stem
from k2 (see equation 3). During the simulations, the
available enzyme concentration [E0] dynamically changes
depending on the substrate concentration although the
condition that [E]total = [E0] + [ES] always holds true.
K
kk
k
m
-1 2
1
=
+ () .2
CL
VS
KS m
=
+ ()
max[]
[]
4
CL
V
K
, if [S] << K
m
m = ()
max
5
Table 2: Physicochemical properties of MDZ, 1OH-MDZ, 1OH-MDZ-Glu and ITZ.
Parameter MDZ 1OH-MDZ 1OH-MDZ-Glu ITZ
Lipophilicity (Log MA)a 2.9 2.6 1.4 3.84
funbound 0.024 0.03 0.03 0.016b
Molecular weight (g/mol) 325.8 341.8 517.9 705.6
Effective molecular weight (g/mol) 286.8 (1Cl, 1F) 302.8 (1Cl, 1F) 478.9 (1Cl, 1F) 661.6 (2Cl)
a MA = Membrane Affinity
b Experimental value taken from [42].Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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Volume of distribution
The volume of distribution is an important parameter in
pharmacokinetic studies. Distribution volumes in PK-
Sim® are estimated based on physico-chemical data (Table
2), as described in Willmann et al. [20]. Membrane affin-
ity, as a lipophilicity value, and plasma unbound fraction
were assessed for MDZ and 1OH-MDZ using the Nimbus
Technology (Nimbus Biotechnology, Leipzig, Germany)
[35,36]. 1OH-MDZ-Glu is not commercially available
and there exists no published lipophilicity or unbound
fraction in plasma value. Therefore, the lipophilicity of
1OH-MDZ-Glu was estimated by using the mean logarith-
mic difference of the lipophilicities of other hydroxylated
compounds and their corresponding glucuronides that
were taken from the literature [37] (Table 2). The glucuro-
nide of valproic acid has an ex vivo unbound fraction in
serum that is half that of the parent compound [38]. In
another study that examined the protein binding of three
compounds and their glucuronides, the unbound fraction
of the glucuronide increased by factors of 2.2, 1.3 and 2.6
[39]. For the purposes of the present study, the fraction
unbound in plasma for 1OH-MDZ-Glu was kept the same
as that of 1OH-MDZ (Table 2).
Plasma concentration time data was located for individu-
als who received either MDZ or 1OH-MDZ intravenously
[15] and experimental data were compared to the curves
predicted by the WB-PBPK model using estimated parti-
tion coefficients. Because there was a slight deviation of
predicted to experimental plasma concentration profiles,
the partition coefficients estimated from physico-chemis-
try for MDZ were compared to experimental partition
coefficients, observed in rats and converted for use in
humans, for MDZ [22]. With the carcass value being taken
as that for bone, the correlation revealed that all predicted
partition coefficients agreed with the experimental data
within a factor of three with the exception of blood cells,
bone, fat and lung, (Figure 8). For these tissues, the exper-
imental partition coefficients were used in the MDZ sim-
ulations and the same predicted to experimental
conversion factors were used for these tissues in the WB-
PBPK models for 1OH-MDZ and 1OH-MDZ-Glu. An
independent validation of the 1OH-MDZ-Glu distribu-
tion volume was not possible due to a lack of plasma con-
centration time data following 1OH-MDZ-Glu
administration.
Optimization of velocity-rate Constants for the 
hydroxylation of Midazolam
All relevant model parameters are now defined as
described above with the exception of the biotransforma-
tion parameters. To generate velocity rate constants for the
elimination of MDZ to 1OH-MDZ, individual plasma
concentration time data for MDZ and its metabolite 1OH-
MDZ following intravenous administration were gathered
from Heizmann et al. [11]. Six normal healthy volunteers
with reported body weight and age were enrolled in this
study.
Comparison of observed and predicted tissue/plasma partition coefficients for the various organs (left: log-log plot, right:  enlarged linear plot of the interval [0,3.5]) Figure 8
Comparison of observed and predicted tissue/plasma partition coefficients for the various organs (left: log-log plot, right: 
enlarged linear plot of the interval [0,3.5]). Small symbols indicate individual data reported by Björkmann et al. [22], large sym-
bols denote the mean value for each organ. The solid line represents the identity, the dotted lines mark the region 3-fold-off 
the identity.Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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For each individual from the Heizmann et al. [11] study,
WB-PBPK models were generated for MDZ and 1OH-
MDZ. These two models were coupled and consequently
contained four unknown parameters, 1OH_k1, 1OH_k-1
and 1OH_k2, which describe MDZ hydroxylation by
CYP3A4/5 as in Eq. (1), and a first order elimination rate
of OH-MDZ via an intrinsic clearance CL(1OH), which
describes the glucuronidation of 1OH-MDZ. These four
parameters were simultaneously optimized per individ-
ual, without constraints, in order to obtain the best fit of
the simulated concentration time curves for MDZ and
1OH-MDZ in plasma to the respective experimental data.
The objective function was the root mean squared error
(RMSE) measured as the root of the squared difference
between the predicted and observed plasma concentra-
tions for both compounds. Objective function minimiza-
tion was done using the fminsearch optimization routine
of MatLab [Version 7 (R14), The MathWorks Inc., Natick,
MA, USA].
Optimization of velocity-rate constants for the 
Glucuronidation of 1-hydroxymidazolam
Plasma concentration time data for MDZ, its metabolite
1OH-MDZ and its conjugated metabolite 1OH-MDZ-Glu
following intravenous bolus MDZ administration were
gathered from Kharasch et al. [16]. Data from one typical
representative was available and used here. The coupled
WB-PBPK model for the Kharasch et al. [16] data con-
tained seven unknown parameters, 1OH_k1, 1OH_k-1 and
1OH_k2, Glu_k1, Glu_k-1 and Glu_k2, and CL(Glu). These
seven parameters were simultaneously optimized in order
to obtain the best fit of simulated concentration time
curves for MDZ, 1OH-MDZ and 1OH-MDZ-Glu to the
corresponding experimental data. For the optimization of
the elimination of MDZ to its metabolite 1OH-MDZ, the
results of the previous optimization were used as con-
straints by setting the min and max constraints for 1OH_
k1,-1,2 as half of and two times the min and max values,
respectively, as determined during the optimization of the
six Heizmann et al. [11] individuals. The mean values of
the optimization of the Heizmann et al. [11] data were
used as initial parameters for 1OH_k1,-1,2. The optimiza-
tion of the velocity-rate constants for the metabolization
of 1OH-MDZ to its metabolite 1OH-MDZ-Glu were
unconstrained, as was the first order elimination of 1OH-
MDZ-Glu [CL(Glu)].
Optimization of the velocity rate constants for the Yu et al 
(2004) study data in the Basal state
Individual plasma concentration time data for MDZ and
the sum of its metabolites, 1OH-MDZ and 1OH-MDZ-
Glu, in the basal state were taken from Yu et al. [4]. In this
study, plasma concentrations of MDZ and 1OH-MDZ
were determined (after addition of glucuronidase to the
plasma samples, i. e. 1OH-MDZ concentrations represent
the sum of 1OH-MDZ and 1OH-MDZ-Glu) for nineteen
healthy adults having either the CYP3A5 *1/*1, *1/*3 or
*3/*3 genotype. Individual values for height, body
weight, sex, age and genotype were also provided [4].
A coupled WB-PBPK model was set up for each individual
in the Yu et al. [4] study. Each model contained seven
unknown parameters, 1OH_k1, 1OH_k-1 and 1OH_k2,
Glu_k1, Glu_k-1 and Glu_k2 and CL(Glu). These seven
parameters were again simultaneously optimized as
described above in order to obtain the best fit of simu-
lated concentration time curves for MDZ and the sum of
1OH-MDZ and 1OH-MDZ-Glu to the corresponding
experimental data. The same constraints as above were
used for the optimization of the elimination of MDZ to
1OH-MDZ. The initial values for optimization for Glu_
k1,-1,2are the results of the optimization of the Kharasch et
al. data[16]. As Kharasch et al. [16] presented data from
only one individual, there were no minima and maxima
which could be used as constraints, therefore no con-
straints were used for the 1OH-MDZ-Glu parameters.
Itraconazole CYP3A4 inhibition model
Itraconazole (ITZ) and its metabolites competitively
inhibit CYP3A4 [13]. The major, and only significant,
metabolite in vivo is hydroxyitraconazole (OH-ITZ)
which is found at concentrations higher than ITZ in
plasma [17].
First, a WB-PBPK model for ITZ was developed using the
physicochemical properties as presented in Table 2. Elim-
ination, representing CYP3A metabolism, was defined as
a Michaelis-Menten process in the liver with a Km of 3.9
ηM [13] and a Vmax to fit the terminal phase of the plasma
concentration profile from Barone et al. [17].
According to the study protocol in Yu et al. [4], the volun-
teers received a single oral dose of a commercial ITZ tab-
let, Sporanox® (Janssen Pharmaceutica), in the fasted state
over five days. Since the pharmacokinetics of ITZ and OH-
ITZ were not assessed by Yu et al., the literature was
searched for similar pharmacokinetic data. Barone et al.
[17] provided plasma concentration time data for Spo-
ranox® tablets, but administered in the fed state. ITZ is a
basic compound with a pKa of 3.7, and it is well known
that administration of ITZ together with food increases
the bioavailability due to a longer retention of the tablet
in the stomach. Consequently, a modified dissolution
profile had to be generated for the Sporanox® tablet in the
fasted state. Sporanox® tablets are well dissolved in acidic
solutions and, within 45 minutes, 50% are dissolved in an
artificial stomach solution [40]. In contrast, in Fed State
Simulating Intestinal Fluid (FeSSIF), Sporanox® tablets
reach a maximum fraction dissolved of 2% in 30 minutes
[40]. In the WB-PBPK model, dissolution was set as 9, 35,Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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50% dissolved in 15, 30 and 45 minutes (the average
length of time the tablets reside in the stomach in the fed
state) to 52% in 75 minutes (2% being the maximum dis-
solution in the intestines). Further, ITZ is metabolized by
CYP3A in the intestine. To account for gut wall metabo-
lism, in each intracellular section of the gastrointestinal
tract (duodenum, jejunum, ileum), a Michaelis-Menten
process in the gut wall was assumed with a Km the same as
that for hepatic metabolism (3.9 nM). A Vmax value for gut
wall metabolism was fit to best represent the absorption
phase of the Barone et al. [17] data. Only one Vmax
required fitting since the proportions of CYP3A in each
intestinal section are known (duodenum: jejunum: ileum
= 9.5: 6.3: 1) [41]. The resulting single dose administra-
tion simulation was fit to experimental data from Barone
et al. [17].
ITZ and OH-ITZ are primarily metabolized by CYP3A4.
Since both have a high affinity for CYP3A4, saturation of
the enzymes can lead to non-linear kinetics. Following
multiple administrations, ITZ and OH-ITZ clearances are
reduced and the concentrations in plasma of the two sub-
stances increase as well as the half-lives. In the Yu et al. [4]
study, ITZ was administered once-daily for five days and
on the fifth day given in conjunction with an IV mida-
zolam bolus. To simulate the likely ITZ concentrations
over 6 days, the time dependence of ITZ elimination was
assessed using the data of Hardin et al. [18]. In this study,
trough plasma concentrations were taken at days 2, 7, 11
and 13 during 200 mg once-daily administrations of ITZ
in the fed-state. Vmax at time 0 was the same as that previ-
ously defined from the single dose study of Barone et al.
[17]. The Vmax was reduced daily to fit the trough concen-
trations from Hardin et al. [18] (Figure 7).
The next step was to generate the fasted state ITZ and OH-
ITZ liver unbound concentration time profiles that will be
used to calculate the time specific CYP3A activity reduc-
tion (see next section). Since most literature data provid-
ing pharmacokinetic profiles of ITZ and OH-ITZ were
those following ITZ administration in the fed state, from
the multiple dose ITZ fed-state profiles (as described
above), both the ITZ and OH-ITZ fasted-state profiles
needed to be generated. Since the difference between the
fed and fasted state plasma profiles are mainly due to dif-
ferences in tablet dissolution, concentration differences
over 24 hours are primarily the ratio of AUCs (AUCfed =
1.7*AUCfasted) [17]. This ratio remained the same
throughout a 15 day BID administration regimen [17].
Therefore, the unbound concentrations in the liver intrac-
ellular space were taken from the WB-PBPK model for
ITZfed and divided by 1.7 to generate the relevant concen-
trations for ITZfasted. For OH-ITZfasted, the AUC ratio of
ITZfed to OH-ITZfasted was used to generate concentrations
where AUCOH-ITZ,fasted = 1.6* AUCITZ,fed [17]. The relevant
liver concentrations were therefore the ITZfed unbound
liver concentrations multiplied by 1.6 and divided by the
ratio of unbound fractions (fu,ITZ/fu,OH-ITZ  = 0.8). The
unbound fraction of OH-ITZ is not available in the litera-
ture therefore the same ratio of parent to hydroxylated fu,
as was determined for MDZ (Table 2), was used.
The effect of the unbound ITZ and OH-ITZ concentrations
on CYP3A4 activity in vitro using MDZ hydroxylation as
an endpoint has been assessed by Isoherranen et al. [13]
and is presented in Figure 9. The unbound ITZ and OH-
ITZ concentrations in the intracellular space of the liver, as
obtained by the WB-PBPK model, were used in conjunc-
tion with Figure 9 to generate a remaining percentage of
CYP3A activity. At each time step, a new CYP3A concen-
tration ([CYP3Ai]) was calculated using the following
equation:
[CYP3Ai] = [CYP3A]*ITZfrac·act *OH - ITZfrac·act   (6)
Here, ITZfrac·act and OH-ITZfrac·act are the fraction of the
initial CYP3A activity based on ITZ and OH-ITZ concen-
trations from Figure 9 (constrained to values between 0
and 1).
Prediction of MDZ and MDZ metabolite pharmacokinetic 
profiles following ITZ administration
Coupling of the previously established MDZ and ITZ
models (a total of 5 WB-PBPK models) finally facilitates
Fraction of remaining CYP3A activity in pooled human liver  microsomes in relation to the unbound inhibitor concentra- tions of ITZ and OH-ITZ Figure 9
Fraction of remaining CYP3A activity in pooled human liver 
microsomes in relation to the unbound inhibitor concentra-
tions of ITZ and OH-ITZ. Data points, as taken from Isoher-
ranen et al. [13], were fit to a logistic, 3 parameter model and 
the equations were used to generate a percentage of CYP3A 
activity remaining, constrained between 0 and 1.Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
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the prediction of the effect of ITZ and OH-ITZ CYP3A
inhibition in the pharmacokinetics of MDZ and its metab-
olites. The coupling was done such that the clearance of
MDZ was affected by the changing concentrations of free
CYP3A [Eo] as defined from the ITZ inhibition model
(Figure 10). WB-PBPK Simulations were performed for
each of the individuals in the Yu et al. [4] study. All veloc-
ity-rate constants as well as CL(Glu) were fixed to the opti-
mized values determined previously in the simulations
for the basal state for each individual. Results were com-
pared to the MDZ and 1OH-MDZ + 1OH-MDZ-Glu
plasma concentration profiles. In summary, the assump-
tions of this combined model were:
1/ MDZ and metabolite elimination kinetics can be adequately
described using Michaelis-Menten kinetics.
2/ The 1'-hydroxylation step is the only significant route of
elimination for midazolam from the body. 4OH-MDZ and
1,4-di-OH-MDZ plasma pharmacokinetic profiles are not
published since they are not found in significant amounts
in plasma [15]. Furthermore, as the percentage of admin-
istered drug excreted in the urine as 4OH-MDZ and 1,4-
di-OH-MDZ (or their glucuronides) is less than 4%, sug-
gesting that these MDZ elimination pathways are not sig-
nificant.
3/ The physico-chemical properties of the compounds were ade-
quate to describe the compound's distribution volume. This was
independently evaluated for MDZ, 1OH-MDZ and ITZ
using experimental plasma concentration time data fol-
lowing IV administration and using some MDZ experi-
mental partition coefficients.
4/ The CYP3A complex was adequate to describe all (CYP3A4
and CYP3A5) CYP3A metabolic processes.
5/ ITZ and OH-ITZ affect the total active CYP3A concentra-
tion in the liver.
6/ ITZ and OH-ITZ unbound liver intracellular concentrations
were adequate representations of actual concentrations in the
volunteers from the Yu et al. [4]study.
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inetic
Competing interests
MV, MS, CN, SW, and ANE are employees of Bayer Tech-
nology Services GmbH.
Authors' contributions
MV designed and performed the basal state MDZ simula-
tions, MS conceptualized and designed the computational
Schematic representation of the inhibition of the CYP3A4- catalyzed MDZ hydroxylation by ITZ and its major metabo- lite OH-ITZ (a) and the simplified model used in this study  (b) Figure 10
Schematic representation of the inhibition of the CYP3A4-
catalyzed MDZ hydroxylation by ITZ and its major metabo-
lite OH-ITZ (a) and the simplified model used in this study 
(b).Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
Page 14 of 15
(page number not for citation purposes)
system to perform the simulations, CN and SW provided
valuable inputs into the conceptual design of the study
and helped to draft the manuscript, IJ provided experi-
mental data and data interpretation for the study, and
ANE conceived of the study and designed and performed
the inhibited state MDZ-ITZ simulations. All authors read
and approved the final manuscript.
Acknowledgements
Bayer Technology Services GmbH provided funding to MV to perform this 
study during a student internship.
References
1. Bachmann KA: Inhibition constants, inhibitor concentrations
and the prediction of inhibitory drug drug interactions: pit-
falls, progress and promise.  Curr Drug Metab 2006, 7:1-14.
2. Brown HS, Ito K, Galetin A, Houston JB: Prediction of in vivo
drug-drug interactions from in vitro data: impact of incorpo-
rating parallel pathways of drug elimination and inhibitor
absorption rate constant.  Br J Clin Pharmacol 2005, 60:508-518.
3. Galetin A, Burt H, Gibbons L, Houston JB: Prediction of time-
dependent CYP3A4 drug-drug interactions: impact of
enzyme degradation, parallel elimination pathways, and
intestinal inhibition.  Drug Metab Dispos 2006, 34:166-175.
4. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS,
Yi SY, Liu KH, Shin JG, Shin SG: Effect of the CYP3A5 genotype
on the pharmacokinetics of intravenous midazolam during
inhibited and induced metabolic states.  Clin Pharmacol Ther
2004, 76:104-112.
5. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic
cytochrome P450 3A4.  Toxicology 1995, 104:1-8.
6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly
A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K,
Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E:
Sequence diversity in CYP3A promoters and characteriza-
tion of the genetic basis of polymorphic CYP3A5 expression.
Nat Genet 2001, 27:383-391.
7. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz
EG, Thummel KE: Co-regulation of CYP3A4 and CYP3A5 and
contribution to hepatic and intestinal midazolam metabo-
lism.  Mol Pharmacol 2002, 62:162-172.
8. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N,
Glodowski M, Thummel KE: Evidence of significant contribution
from CYP3A5 to hepatic drug metabolism.  Drug Metab Dispos
2004, 32:1434-1445.
9. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr
DM, Gillies BS, Thummel KE: First-pass metabolism of mida-
zolam by the human intestine.  Clin Pharmacol Ther 1996,
60:14-24.
10. de Wildt SN, de HM, Vinks AA, van der GE, van den Anker JN: Pop-
ulation pharmacokinetics and metabolism of midazolam in
pediatric intensive care patients.  Crit Care Med 2003,
31:1952-1958.
11. Heizmann P, Eckert M, Ziegler WH: Pharmacokinetics and bioa-
vailability of midazolam in man.  Br J Clin Pharmacol 1983, 16
Suppl 1:43S-49S.
12. Fraser AD, Bryan W, Isner AF: Urinary screening for midazolam
and its major metabolites with the Abbott ADx and TDx
analyzers and the EMIT d.a.u. benzodiazepine assay with
confirmation by GC/MS.  J Anal Toxicol 1991, 15:8-12.
13. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE: Role
of itraconazole metabolites in CYP3A4 inhibition.  Drug Metab
Dispos 2004, 32:1121-1131.
14. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W:
PK-Sim®: a physiologically based pharmacokinetic 'whole-
body' model.  Biosilico 2003, 1:121-124.
15. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF,
Danhof M: Pharmacokinetic-pharmacodynamic modeling of
the central nervous system effects of midazolam and its
main metabolite alpha-hydroxymidazolam in healthy volun-
teers.  Clin Pharmacol Ther 1992, 51:715-728.
16. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle
A, Cox K: The role of cytochrome P450 3A4 in alfentanil
clearance. Implications for interindividual variability in dis-
position and perioperative drug interactions.  Anesthesiology
1997, 87:36-50.
17. Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC,
Moskovitz BL, Mechlinski W, Van V V: Food interaction and
steady-state pharmacokinetics of itraconazole capsules in
healthy male volunteers.  Antimicrob Agents Chemother 1993,
37:778-784.
18. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG,
Kuhn JG: Pharmacokinetics of itraconazole following oral
administration to normal volunteers.  Antimicrob Agents Chem-
other 1988, 32:1310-1313.
19. Özdemir MC K., Tucker G, Rostami-Hodjegan A: The impact of
ketoconazole (KTZ) dosage regimen on midazolam clear-
ance and its prediction using PBPK modelling.  Eur J Pharm Sci
2006, In Press:Abstract of the European Federation for Pharmaceu-
tical Sciences Conference on Optimising Drug Development together
with BioSim EU Network of Excellence, Basel, Switzerland, Nov 29 -
Dec 1, 2006..
20. Willmann S, Lippert J, Schmitt W: From physicochemistry to
absorption and distribution: predictive mechanistic model-
ling and computational tools.  Expert Opin Drug Metab Toxicol
2005, 1:159-168.
21. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB: A phys-
iological model for the estimation of the fraction dose
absorbed in humans.  J Med Chem 2004, 47:4022-4031.
22. Bjorkman S, Wada DR, Berling BM, Benoni G: Prediction of the
disposition of midazolam in surgical patients by a physiolog-
ically based pharmacokinetic model.  J Pharm Sci 2001,
90:1226-1241.
23. Patki KC, Von Moltke LL, Greenblatt DJ: In vitro metabolism of
midazolam, triazolam, nifedipine, and testosterone by
human liver microsomes and recombinant cytochromes
p450: role of cyp3a4 and cyp3a5.  Drug Metab Dispos 2003,
31:938-944.
24. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S:
No ethnic difference between Caucasian and Japanese
hepatic samples in the expression frequency of CYP3A5 and
CYP3A7 proteins.  Biochem Pharmacol 1999, 57:935-939.
25. Reinach B, de SG, Dostert P, Ings R, Gugenheim J, Rahmani R: Com-
parative effects of rifabutin and rifampicin on cytochromes
P450 and UDP-glucuronosyl-transferases expression in fresh
and cryopreserved human hepatocytes.  Chem Biol Interact 1999,
121:37-48.
26. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K,
Hamman MA, Hall SD, Wrighton SA: Comparative metabolic
capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab
Dispos 2002, 30:883-891.
27. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H:
CYP3A5 genotype and midazolam clearance in Australian
patients receiving chemotherapy.  Clin Pharmacol Ther 2004,
75:529-538.
28. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R,
Lim HL, Ong AB, Lee HS: Explaining interindividual variability
of docetaxel pharmacokinetics and pharmacodynamics in
Asians through phenotyping and genotyping strategies.  J Clin
Oncol 2002, 20:3683-3690.
29. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr., Bhat K,
Kim RB, Wilkinson GR: Genotype-phenotype associations for
common CYP3A4 and CYP3A5 variants in the basal and
induced metabolism of midazolam in European- and Afri-
can-American men and women.  Pharmacogenetics 2003,
13:595-606.
30. Shih PS, Huang JD: Pharmacokinetics of midazolam and 1'-
hydroxymidazolam in Chinese with different CYP3A5 geno-
types.  Drug Metab Dispos 2002, 30:1491-1496.
31. Willmann S, Hoehn K, Edginton AN, Sevestre M, Solodenko J, Lippert
J, Schmitt W: Development of a physiology-based whole-body
population model for assessing the influence of individual
variability on the pharmacokinetics of drugs.  J Pharmacokinet
Pharmacodynam 2006, In Press:.
32. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW,
Tucker GT: Inter-individual variability in levels of humanPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Theoretical Biology and Medical Modelling 2007, 4:13 http://www.tbiomed.com/content/4/1/13
Page 15 of 15
(page number not for citation purposes)
microsomal protein and hepatocellularity per gram of liver.
Br J Clin Pharmacol 2003, 56:433-440.
33. Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE,
Tyson CA, Yokoi T, Kamataki T, Sugiyama Y: Prediction of in vivo
hepatic metabolic clearance of YM796 from in vitro data by
use of human liver microsomes and recombinant P-450 iso-
zymes.  J Pharmacol Exp Ther 1997, 282:909-919.
34. Houston JB: Utility of in vitro drug metabolism data in pre-
dicting in vivo metabolic clearance.  Biochem Pharmacol 1994,
47:1469-1479.
35. Loidl-Stahlhofen A, Hartmann T, Schottner M, Rohring C, Brodowsky
H, Schmitt J, Keldenich J: Multilamellar liposomes and solid-sup-
ported lipid membranes (TRANSIL): screening of lipid-
water partitioning toward a high-throughput scale.  Pharm Res
2001, 18:1782-1788.
36. Loidl-Stahlhofen A, Eckert A, Hartmann T, Schottner M: Solid-sup-
ported lipid membranes as a tool for determination of mem-
brane affinity: high-throughput screening of a
physicochemical parameter.  J Pharm Sci 2001, 90:599-606.
37. Ramu K, Baker JK: Identification of the glucuronides of the
hydroxylated metabolites of the antimalarial arteether in
rat plasma and urine by thermospray high-performance liq-
uid chromatography/mass spectrometry.  J Pharm Sci 1997,
86:915-920.
38. Brouwer KL, Hall ES, Pollack GM: Protein binding and hepatobil-
iary distribution of valproic acid and valproate glucuronide in
rats.  Biochem Pharmacol 1993, 45:735-742.
39. Ishii M, Kanayama M, Esumi H, Ogawara KI, Kimura T, Higaki K:
Pharmacokinetic analysis of factors determining elimination
pathways for sulfate and glucuronide metabolites of drugs. I:
studies by in vivo constant infusion.  Xenobiotica 2002,
32:441-450.
40. Leuner C: Verbesserung des Freisetzungsverhaltens von Itra-
conazol durch feste Dispersionen.  Ph D Thesis 2004:Fachbereich
Chemische und Pharmazeutische Wissenschaften der Johann Wolf-
gang Goethe-Universitaet in Frankfurt am Main, Frankfurt, Germany.
41. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Per-
kins JD, Thummel KE: Characterization of interintestinal and
intraintestinal variations in human CYP3A-dependent
metabolism.  J Pharmacol Exp Ther 1997, 283:1552-1562.
42. Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W,
Ikeda T, Komai T, Ito K, Sugiyama Y: Inhibition of in vitro metab-
olism of simvastatin by itraconazole in humans and predic-
tion of in vivo drug-drug interactions.  Pharm Res 2001,
18:622-631.